Background: Edge-to-edge percutaneous mitral valve repair has emerged as an alternative to surgery in high-risk patients. However, data with regard to its safety and efficacy in real-world patients are still scarce. The aim of this prospective multinational registry is to present a real-world overview of MitraClip use focusing on patient characteristics, clinical indication, technique, in-hospital and mid-term outcome. Methods: The Transcatheter Valve Treatment Sentinel Pilot Registry is a prospective independent consecutive collection of individual patient data entered into a web-based case record form (CRF). Results: A total of 587 patients (mean age 74.7AE9.5 years, 64.1 % male) underwent MitraClip implantation between January 2011 and December 2012 in 25 centres of 8 European countries. The prevalent etiology was functional MR (FMR; 414 patients, 70.5%) while 150 patients (25.5%) were diagnosed as having degenerative MR (DMR), with the remaining patients (23, 4.0%) classified as mixed aetiology or MR of unknown origin.Logistic EuroSCORE was high (19.9AE16.0%). Successful deployment of at least 1 clip was achieved in 95.9% of patients, with a trend to higher implantation success in the FMR group (p¼0.087). Acute procedural success was high (97.3%) and equivalent between groups (p¼1.000). One clip was implanted in the majority of cases (60.7%), two clips were implanted in 35.9% of cases and a small minority received 3 or more clips (3.4%). Patients with DMR tended to receive a greater number of clips (!2 clips implanted in 43.5% of patients with DMR vs. 37.4% of patients with FMR, p¼0.191) than those with functional mitral regurgitation. Echocardiograms prior to discharge showed a marked reduction in mitral insufficiency to 2+ in 98.2% of patients, with equivalence between groups. In-hospital mortality was low (2.0%) and without significant differences between groups, although DMR group had a trend to higher mortality. Clinical and echo follow-up data at 6-12 month will be available at the time of presentation.
Conclusions: this truly independent and contemporary registry of MitraClip implantation shows that the technique is effective and is associated with low complication rate.
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Targeting Background: Hypertrophic obstructive cardiomyopathy (HOCM) with left ventricular outflow tract obstruction frequently involves a systolic anterior motion (SAM) of the anterior mitral leaflet. We hypothesized, that SAM could be a new target for MitraClip therapy. Methods: Four patients with HOCM were chosen for MitraClip therapy, due to significant SAM with subsequent mitral regurgitation. Invasive hemodynamic studies (right heart catheterization, simultaneous transaortic pressure recording, administration of nitroglycerin) before and after MitraClip implantation in addition to 6 weeks follow-up were performed. Results: MitraClip implantation was successfully performed with significant reduction of mitral regurgitation and SAM in all patients. Basal peak gradients (before Clip: 56AE27 mmHg; after clip: 10AE6 mmHg) as well as provoked pressure gradients (before clip: 134AE23 mmHg; after clip: 21AE8 mmHg) were significantly reduced after MitraClip. Right heart catheterization data did not reveal major changes. At 6-weeks follow-up, all patients presented in a persistent improved clinical state (NYHA class I-II) with insignificant residual MR and continuously reduced LVOT gradients. Conclusions: This is the first catheter-based study targeting primarily a SAM in HOCM to reduce LVOT obstruction. The results prove the concept, that SAM is more than an epiphenomenon in HOCM. Thus, SAM-induced obstruction might be a valuable target for the MitraClip.
TCT-88
Outcomes of Cardiac Surgery are Preserved Following the MitraClip Procedure. Background: Transcatheter mitral valve repair with the MitraClip is a safe procedure for severe mitral regurgitation (MR). A reported higher mitral valve replacement rate following the MitraClip resulted in an overstated complexity of subsequent surgery and its implications on patient outcomes. This study will review the outcomes of cardiac surgery following MitraClip procedure. Methods: Of the 157 consecutive patients that underwent the MitraClip procedure in our center, 16 (10%) required cardiac surgery. These patients (mean 67AE12 years old, 7 (44%) women) with Society of Thoracic Surgeons mortality score of 0.5 to 17.1% were reviewed in regards to their operative details and outcomes. The mean implant duration was 12.5 months (range 14 days to 75 months).
Results: No patient required urgent cardiac surgery for failed MitraClip procedure. Of the 9 patients with degenerative MR, 8 were repaired and 1 had a replacement for MitraClip endocarditis. Robotic assisted repair occurred in one patient that had no implanted clip whilst 2 had one clip, and 3 had two clips; the implant duration ranged from 2.5 months to 6.3 years. Of the 7 patients with functional MR, 5 had replacement and 2 required heart transplantation for severe heart failure. There was no operative 
